

Total fluid intake and the risk of recurrence in patients with non-muscle invasive bladder cancer:

Jochems, Sylvia; Van Osch, Frits; Reulen, Raoul; van Hensbergen, Mitch ; Nekeman, Duncan; Pirrie, Sarah; Wesselius, Anke; van Schooten, Frederik J; James, Nicholas; Michael Wallace, A; Bryan, Richard; Cheng, Kar; Zeegers, Maurice

DOI:
[10.3233/BLC-180172](https://doi.org/10.3233/BLC-180172)

License:
None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):
Jochems, S, Van Osch, F, Reulen, R, van Hensbergen, M, Nekeman, D, Pirrie, S, Wesselius, A, van Schooten, FJ, James, N, Michael Wallace, A, Bryan, R, Cheng, K & Zeegers, M 2018, 'Total fluid intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study', *Bladder Cancer*, vol. 4, no. 3, pp. 303-310. <https://doi.org/10.3233/BLC-180172>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:
Final Version of Record forthcoming in *Bladder Cancer* - <http://www.bladdercancerjournal.com/>

General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 Total fluid intake and the risk of recurrence in patients with non-muscle invasive bladder
2 cancer: a prospective cohort study

3

4 Sylvia H.J. Jochems* (1, 2), Frits H.M. van Osch (1, 2), Raoul C. Reulen (3), Mitch van
5 Hensbergen (2), Duncan Nekeman (1), Sarah J. Pirrie (1), Anke Wesseliuss (2), Frederik J.
6 van Schooten (2), Nicholas D. James (1, 4), D. Michael A. Wallace (1, 4), Richard T. Bryan
7 (1), K.K. Cheng (3), Maurice P. Zeegers (1, 2)

8

9 (1) Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham,
10 United Kingdom

11 (2) School for Nutrition and Translational Research in Metabolism, Maastricht
12 University, The Netherlands

13 (3) Institute of Applied Health Research, department of Public Health, Epidemiology and
14 Biostatistics, University of Birmingham, United Kingdom

15 (4) University Hospital Birmingham, NHS Foundation Trust, Birmingham, United
16 Kingdom

17

18 *Corresponding author contact information: Sylvia H.J. Jochems, Maastricht University, Department
19 of Complex Genetics and Epidemiology, PO Box 616, 6200 MD Maastricht, the Netherlands

20 Email: s.jochems@maastrichtuniversity.nl

21

22 Keywords: fluid intake, bladder cancer, recurrence

23

24

25 **ABSTRACT**

26 **Objectives:** To investigate the role of fluid intake from beverages before and after a
27 diagnosis of bladder cancer in relation to the risk of developing bladder cancer recurrence.

28 **Study design:** Prospective cohort study. **Methods:** 716 patients with non-muscle invasive
29 bladder cancer (NMIBC), who received transurethral resection of a primary bladder tumour
30 (TURBT) and completed self-administrated questionnaires on usual fluid intake from
31 beverages at time of diagnosis (over the year before diagnosis) and during follow-up (over
32 the year after diagnosis), were included. Multivariable Cox regression was used to calculate
33 hazard ratios and 95% confidence intervals of developing recurrent bladder cancer in relation
34 to the intake of total fluid, total alcohol, and individual beverages. **Results:** During 2,025
35 person-years of follow-up, 238 (33%) of the included 716 NMIBC patients developed one or
36 more recurrences of bladder cancer. Total fluid intake before diagnosis was not associated
37 with a first recurrence of bladder cancer when comparing the highest and lowest intake group
38 (HR=0.98, 95% C.I. 0.70-1.38, p=0.91). Comparable results were obtained for total fluid
39 intake pre-diagnosis and the risk of developing multiple recurrences of bladder cancer
40 (HR=1.01, 95% C.I. 0.87-1.19, p=0.85). A total of 379 of the 716 patients reported on usual
41 fluid intake within 1 year of diagnosis. No significant associations between total fluid intake
42 1 year after diagnosis and a first recurrence of bladder cancer were found when comparing
43 the highest and lowest intake group (HR=0.91; 95% C.I. 0.60-1.37, p=0.65) or with multiple
44 recurrences of bladder cancer (HR=1.06; 95% C.I. 0.89-1.26, p=0.54). In addition, total
45 alcohol intake and individual beverages were not associated with bladder cancer recurrence.
46 **Conclusions:** The results indicate that an individual's fluid intake from beverages is unlikely
47 to have an important role in bladder cancer recurrence.

48

49 **INTRODUCTION**

50 Non-muscle-invasive bladder cancer (NMIBC) is the most common malignancy of the
51 urinary tract and has a high rate of recurrence despite adequate therapy. Identification of
52 modifiable risk factors could reduce the risk of developing recurrences and improve
53 prognosis. The urogenous contact theory hypothesizes that an increased voiding frequency
54 may reduce bladder cancer risk [1,2]. By increasing the intake of fluids, potential carcinogens
55 present in the urine are diluted and the voiding frequency stimulated. By reducing the contact
56 time of carcinogens with the bladder urothelium, the risk of bladder cancer decreases. On the
57 contrary, it has been suggested that when the bladder wall is extended from a high volume of
58 urine, carcinogens can come into contact with deeper layers of the bladder urothelium and
59 increase bladder cancer risk [3]. In addition, in some parts of the world drinking water
60 contaminated with a high concentration of arsenic could increase the risk of bladder cancer
61 [4]. It is conceivable that the theories about fluid intake and the risk of developing bladder
62 cancer represent a modifiable factor of importance in bladder cancer prognosis as well [5–7];
63 it would be a compelling strategy to simply increase or decrease fluid intake to decrease the
64 risk of recurrence. To our knowledge, only Donat *et al.* [8] investigated the impact of total
65 fluid intake on tumour recurrence in patients with NMIBC. At each visit, all patients
66 undergoing surveillance for recurring tumours completed a self-administered fluid intake
67 questionnaire that measured total fluid intake during a 24-hour period. Results of this study
68 indicated that daily fluid intake levels did not affect recurrence and that the types of fluids
69 imbibed may be more important than the total amount [8]. Therefore, the present study
70 investigates the role of individual beverages, total alcohol and total fluid intake (over the year
71 before and the year after diagnosis) and the risk of developing one or more recurrences of
72 bladder cancer.

METHODS

The Bladder Cancer Prognosis Programme

This study is part of the Bladder Cancer Prognosis Programme (BCPP), a prospective cohort study in the West Midlands region of England. Details of the cohort have been published previously [9]. Briefly, during the enrolment period (December 2005 - October 2011), a total of 1,550 male and female patients (age ≥ 18 years) were enrolled based on abnormal cystoscopic findings suggestive of bladder cancer. Transurethral resection of the primary bladder tumour (TURBT) was followed by cystoscopic surveillance. Optimal additional treatment comprised intravesical chemotherapy with mitomycin C within 24 hours of TURBT and/or a course of further mitomycin C or intravesical BCG, as per contemporary European Association of Urology guidelines. Bladder cancer recurrence was defined as the new occurrence of a non-muscle invasive bladder cancer (stage Ta, T1, or pTis) at the same or at a different site as the initial primary bladder tumour and excluding recurrence identified at the first check cystoscopy. Written informed consent was obtained from all participants. The study protocol was approved by the Nottingham Research Ethics Committee (06/MRE04/65) and registered on ClinicalTrials.gov (NCT00553566).

Data collection

Around the time of diagnosis, just prior to, or just post TURBT, data on medical history, socio-demographics, quality of life, and health-related lifestyle (including dietary intake) were collected by a trained research nurse using semi-structured face-to-face interviews and a questionnaire. The research nurse and patient went through the questionnaire page by page. Patients were asked about habitual dietary intake over the previous year. The developed version of the food-frequency questionnaire (FFQ) aims to assess the dietary intake, by asking the participants to report the frequency of consumption of approximately 16-line items

over the last year. More specifically, the frequency of fluid intake from beverages asked in the questionnaire consisted of six levels: never or less than once per month, one to three times per month, once a week, two to four times per week, five to six times per week, or at least once per day. For each drink, a measure size was provided (e.g. cup, (small) glass, pub measure (2.5cl), or (half) pint glass). The frequency of intake of each beverage was multiplied by their measure size to calculate the millilitres of fluids consumed per day. Total fluid intake was computed as the sum of servings of all beverages in the questionnaire: wine-champagne, fortified wine, beer, cider, spirits, liqueurs, coffee, tea, hot chocolate, soup, ovaltine-horlicks, fizzy pop, pure fruit juice, fruit squash, milk, and water. Total alcohol intake included alcoholic beverages only: wine-champagne, fortified wine, beer, cider, spirits, and liqueurs. Repeated fluid intake from beverages was collected through a postal follow-up questionnaire one year after diagnosis.

Exclusion criteria

A total of 244 participants with no evidence of a bladder tumour (T0), patients who had a tumour that could not be assessed (Tx) (n=116), who had muscle invasive bladder cancer (MIBC) (n=275), who received no TURBT (n=16), who had radiotherapy (on suspicion of MIBC) (n=8), who had incomplete data on tumour characteristics (e.g. stage, grade, size, multiplicity) (n=53) and smoking (n=94), and had missing data on pre-diagnosis fluid intake (n=28), were all excluded from this study (Figure 1). The final analysis for fluid intake over the year before diagnosis comprised 716 patients. More than a third of these 716 patients did not complete a follow-up questionnaire one year after diagnosis (n=278) or developed a recurrence of bladder cancer before completing the follow-up questionnaire (n=59). Therefore, a total of 379 patients remained for investigating the association between fluid intake over the year after diagnosis and bladder cancer recurrence.

Statistical Analysis

According to the UK government recommendations on eating healthy and achieving a balanced diet, anybody living in a maritime climate should consume at least 1,200 mL of fluids from drinks a day [10]. Patients were divided into three groups: a group with an intake of 250mL – 850mL of total fluid per day, a group consuming 850mL – 1,200 mL of total fluid per day, or a group with a total intake of more than the recommended 1,200 mL of fluid per day. Patients became at risk for a recurrence of bladder cancer from the date of TURBT and remained at risk until the earliest occurrence of a recurrence, cystectomy, death, the most recent surveillance cystoscopy, or study end (five years post-TURBT). Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (95% C.I.) of developing a first recurrence of bladder cancer in relation to total fluid intake, total alcohol intake, and individual beverages. To identify possibly influential outliers in total fluid and alcohol intake, Cook's Distance was used. The association of fluid intake with recurrent bladder cancer was examined in both crude and multivariate models. Confounders were considered *a priori* based on known prognostic factors for NMIBC recurrence from the European Association of Urology guidelines and included: age at diagnosis (continuous) [11], sex (male/female) [12], smoking status (never/former/current smoker) [13], and tumour characteristics including stage (pTa/pT1/pTis), grade (1/2/3), size of largest tumour (diameter <3cm/≥3cm), and tumour multiplicity (1/>1) [14–16].

Conditional risk set modelling was applied to investigate time to each recurrent event and analysis time was reset at each event [17]. For this analysis, re-resection of tumours (yes/no) was added as a confounder. The proportional hazards assumption was checked in all models using Schoenfeld residuals [18]. Cumulative incidence functions (CIF) accounting for competing risks (death and cystectomy) were made [19]. These models are conditional as the failure times are conditional on the occurrence of the prior recurrence, i.e. a second

recurrence cannot occur before the first recurrence. P-values were 2-sided with a significance level of 0.05. All statistical analyses were performed using Stata software version 14.

RESULTS

Baseline characteristics and number of recurrences

During 2,025 person-years of follow-up (mean (SD) follow-up 3.7 (1.5) years), 238 (33%) of the 716 NMIBC patients developed one or more recurrences of bladder cancer. More specifically, 80 (34%) of these 238 patients developed a second recurrence, 35 (15%) a third recurrence, 17 (8%) a fourth recurrence, five (3%) a fifth recurrence, two (1%) a sixth recurrence, and one (1%) a seventh recurrence. Patient characteristics at diagnosis and initial treatment are presented in Table 1. The median age at diagnosis was 71 years and most patients were male (80%), Caucasian (97%), and current or former smokers (86%). The average intake of fluid was relatively evenly distributed between patients who had a recurrence of bladder cancer and those who had not (mean total fluid intake 1,087 mL per day and 1,103 mL per day, respectively).

Total fluid intake and bladder cancer recurrence

Table 2 presents HRs with corresponding 95% C.I. for total fluid intake over the year before diagnosis from beverages and time to a first bladder cancer recurrence and multiple bladder cancer recurrences among 716 NMIBC patients. Total fluid intake the year before diagnosis did not affect the recurrence of a first bladder tumour (HR= 0.98, 95% C.I. 0.70-1.38, p=0.91) when adjusted for age, sex, smoking status, stage, grade, and tumour size and multiplicity. The association between total fluid intake the year before diagnosis and time to multiple recurrences showed similar results (HR= 1.01, 95% C.I. 0.87-1.19, p=0.85) when adjusted for the same confounders and tumour re-resection (second transurethral resection).

Table 3 presents the results for the remaining 379 NMIBC patients on total fluid intake after diagnosis – no significant associations were observed between total fluid intake and the development of a first bladder cancer recurrence (HR=0.91; 95% C.I. 0.60-1.37, p=0.65) or

multiple recurrences (HR=1.06; 95% C.I. 0.89-1.26, p=0.54) when corrected for known prognostic factors for NMIBC recurrence provided in the European Association of Urology guidelines (including age, sex, smoking status, tumour characteristics and tumour re-resection).

Total alcohol and individual beverages intake and bladder cancer recurrence

Results of the Cox proportional hazard models predicting the development of recurrence based on total alcohol intake and individual beverages can be found in the online supplementary file (Table S1-S8). Among 716 NMIBC patients, total alcohol intake before diagnosis (highest intakes >125mL versus lowest intakes 0mL) was not associated with a first bladder tumour (HR= 0.97; 95% CI 0.70-1.36) in the most extensive model (adjusted for age, sex, smoking status, stage, grade, and tumour size and multiplicity) (Table S1). Similar results were found for total alcohol intake prior to a diagnosis of bladder cancer and multiple recurrences of bladder cancer (HR= 0.97; 95% CI 0.84-1.11) when corrected for the same confounders as in the time to a first recurrence analysis plus re-resection of a bladder tumour (Table S2).

None of the individual alcoholic beverages including beer, cider, wine/champagne, fortified wine, spirits or liqueurs consumed prior to bladder cancer diagnosis influenced the risk of developing a first or multiple recurrences of bladder cancer when comparing the highest frequency of intake 'at least 1 per day' versus the lowest frequency of intake /never/less than 1 per month' (Table S1-S2). The warm beverages coffee, tea, hot chocolate, ovaltine/horlicks and soup were also investigated. No associations were found when comparing the frequencies of these warm beverages (at least one per day versus never/less than 1 per month before diagnosis) and a first or multiple recurrences of bladder cancer (Table S3-S4). In addition, pre-diagnosis consumption of the cold beverages milk, water, fizzy pop, pure fruit juice, and

fruit squash/cordial, did not affect the development of one or multiple recurrences of bladder cancer when comparing the highest versus the lowest frequency intakes.

Among the 379 NMIBC that remained for analyses one year after a diagnosis of bladder cancer, total alcohol intake was not associated with a first recurrence (HR= 1,01; 95% CI 0.65-1.58) or multiple recurrences (HR= 1,05; 95% CI 0.88-1.25) (Table S5-S6). Consumption of alcoholic beverages one year after a diagnosis of bladder cancer was not related to the development of bladder cancer recurrences (Table S5-S6). Finally, no associations were found for usual warm and hot non-alcoholic beverages consumption and one or more recurrence of bladder cancer (Table S7-S8).

DISCUSSION

The results of this study indicate that there is no evidence of an association between total fluid, total alcohol, or individual beverages (before and after diagnosis) and recurrence of a bladder tumour in patients diagnosed for NMIBC. These results are consistent with the findings of Donat *et al.* [8] who also concluded it remains unclear whether increased total fluid intake is beneficial against the development of bladder cancer recurrence. With regard to fluid intake and the risk of developing bladder cancer for the first time, the results of a recent case-control study have shown that there was no association with total water intake from both beverages and foods [20]. Also the results of a meta-analysis demonstrated no association between total fluid intake and the risk of developing primary bladder cancer [21]. However, subgroup analyses indicated that high fluid intake could increase the risk of bladder cancer in European men (and possibly American men) and decrease the risk of bladder cancer in Asian men [21].

It seems plausible, however, that substances in beverages could be involved in carcinogenesis in the bladder as they come into contact with the bladder urothelium when excreted via the urine. The numerous substances may react differently with cells of the bladder urothelium and be involved in several different pathways associated with cancer pathogenesis including inflammation, cell survival and self-renewal of cancer stem cells [22,23]. A possible explanation for the lack of an association between fluid intake from beverages and bladder cancer recurrence could be that tumour recurrence is more influenced by tumour biology, field cancerization, and cancer treatment than continued exposure of potential carcinogens with the bladder urothelium [24–26]. Incomplete resection of the primary tumour and tumour cell re-implantation remain to be the most influential factors in the development of NMIBC recurrence [26]. Finally, it is inevitable that fluid intake was not measured without error -

recall bias and measurement errors in dietary intake cannot be excluded and are a common limitation of epidemiological studies.

CONCLUSIONS

The results of this study indicate that fluid intake from beverages is unlikely to have a dominant role in influencing the risk of subsequent recurrence(s). Proposed strategies aimed at decreasing contact time of carcinogens with the urothelium by increasing fluid intake are unlikely to delay or prevent the development of bladder cancer recurrence in NMIBC patients.

Conflict of Interest statement

All authors certify that they have no affiliations with or involvement in any organisation or entity with any financial interest in the subject matter or materials discussed in this manuscript.

Funding

BCPP was supported by Cancer Research UK, the Institute of Applied Health Research (IAHR), and the Institute of Cancer and Genomic Sciences of the University of Birmingham.

Figure 1. Flow diagram of patients selection, with exclusion criteria




Table legends:

Table 1. Patient characteristics at diagnosis for 716 NMIBC patients treated with transurethral resection of a primary bladder tumour

Table 2. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences of bladder cancer, based on total fluid consumed in the year before diagnosis, in 716 NMIBC patients

Table 3. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences of bladder cancer, based on total fluid consumed in the year after diagnosis, in 379 NMIBC patients

Online Supplemental Tables S1-S8. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences of bladder cancer, based on alcohol intake from beverages and individual beverages consumed in the year before and in the year after diagnosis

Table 1. Patient characteristics at diagnosis for 716 NMIBC patients treated with transurethral resection of a primary bladder tumour

		Number (%)
Age at time of diagnosis (years)		
median (25 th -75 th percentile)	71 (63-77)	
Sex	Male	573 (80%)
	Female	143 (20%)
Smoking status	Current smokers	335 (47%)
	Former smokers	281 (39%)
	Never smokers	100 (14%)
Alcohol consumption	Drinkers	540 (75%)
	Non-drinkers	176 (25%)
Educational level	High	89 (12%)
	Middle	91 (13%)
	None/Low	163 (23%)
BCG intravesical immunotherapy	Yes	111 (15%)
	No	275 (39%)
Mitomycin C intravesical chemotherapy	Yes	337 (47%)
	No	73 (10%)
Tumour stage	pTa	478 (67%)
	pT1	232 (32%)
	pTis	6 (1%)
Tumour grade	1	206 (29%)
	2	261 (36%)
	3	249 (35%)
Size largest tumour (cm)	<3	449 (63%)
	≥3	267 (37%)
Tumours multiplicity	1	427 (59%)
	>1	289 (41%)
No of recurrences over 5 years	0	478 (67%)
	1	158 (22%)
	>1	80 (11%)

Where the data contains missing values the percentages do not add up to 100%

Table 2. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences of bladder cancer, based on total fluid intake over the year before diagnosis, in 716 NMIBC patients

			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	p for trend
Time to first recurrence									
250-850 mL	205	64	ref	.	ref	.	ref	.	0.86
850 – 1200 mL	257	98	1.24 (0.90-1.69)	0.19	1.26 (0.92-1.72)	0.16	1.17 (0.85-1.62)	0.33	
>1200 mL	254	76	0.92 (0.66-1.28)	0.62	0.93 (0.67-1.31)	0.70	0.98 (0.70-1.38)	0.91	
Time to multiple recurrences									
250-850 mL	205	92	ref	.	ref	.	ref	.	0.78
850 – 1200 mL	257	171	0.95 (0.83-1.09)	0.48	0.96 (0.84-1.10)	0.57	0.95 (0.83-1.08)	0.42	
>1200 mL	254	115	1.05 (0.90-1.22)	0.51	1.05 (0.90-1.23)	0.54	1.01 (0.87-1.19)	0.85	

*Model 1 is unadjusted, **Model 2 is adjusted for age, sex, and smoking status, ***Model 3 is adjusted for age, sex, smoking status, tumour stage, grade, size and multiplicity. In the time to multiple recurrences analyses, Model 2 and Model 3 were additionally adjusted for the variable re-resection of a bladder tumour (second transurethral resection)

Table 3. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first and multiple recurrences of bladder cancer, based on total fluid intake over the year after diagnosis, in 379 remaining NMIBC patients

			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	p for trend
Time to first recurrence									
250-850 mL	116	45	ref	.	ref	.	ref	.	0.65
850 – 1200 mL	124	48	1.08 (0.72-1.63)	0.71	1.04 (0.69-1.57)	0.86	1.07 (0.71-1.61)	0.76	
>1200 mL	139	46	0.81 (0.54-1.21)	0.31	0.80 (0.53-1.20)	0.27	0.91 (0.60-1.37)	0.65	
Time to multiple recurrences									
250-850 mL	116	67	ref	.	ref	.	ref	.	0.53
850 – 1200 mL	124	71	1.07 (0.91-1.25)	0.41	1.06 (0.91-1.24)	0.43	1.08 (0.91-1.27)	0.38	
>1200 mL	139	68	1.05 (0.87-1.26)	0.63	1.04 (0.86-1.26)	0.67	1.06 (0.89-1.26)	0.54	

*Model 1 is unadjusted, **Model 2 is adjusted for age, sex, and smoking status, ***Model 3 is adjusted for age, sex, smoking status, tumour stage, grade, size and multiplicity. In the time to multiple recurrences analyses, Model 2 and Model 3 were additionally adjusted for the variable re-resection of a bladder tumour (second transurethral resection)

REFERENCES

- [1] Silverman DT, Hartge P, Morrison AS, Devesa SS. Epidemiology of bladder cancer. *Hematol Oncol Clin North Am* 1992;6:1–30.
- [2] McDONALD DF, LUND RR. The role of the urine in vesical neoplasm. I. Experimental confirmation of the urogenous theory of pathogenesis. *J Urol* 1954;71:560–70.
- [3] Claude J, Kunze E, Frentzel-Beyme R, Paczkowski K, Schneider J, Schubert H. Life-style and occupational risk factors in cancer of the lower urinary tract. *Am J Epidemiol* 1986;124:578–89.
- [4] World Cancer Research Fund International/American Institute for Cancer Research. Continuous Update Project Report: Diet, Nutrition, Physical Activity and Bladder Cancer. 2015. n.d.
- [5] Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Curhan GC, Willett WC, et al. Fluid intake and the risk of bladder cancer in men. *N Engl J Med* 1999;340:1390–7. doi:10.1056/NEJM199905063401803.
- [6] Zhou J, Smith S, Giovannucci E, Michaud DS. Reexamination of total fluid intake and bladder cancer in the health professionals follow-up study cohort. *Am J Epidemiol* 2012;175:696–705. doi:10.1093/aje/kwr359.
- [7] Pekmezi DW, Demark-Wahnefried W. Updated evidence in support of diet and exercise interventions in cancer survivors. *Acta Oncol* 2011;50:167–78. doi:10.3109/0284186X.2010.529822.
- [8] Donat SM, Bayuga S, Herr HW, Berwick M. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. *J*

Urol 2003;170:1777–80. doi:10.1097/01.ju.0000091803.35049.da.

- [9] Zeegers MP, Bryan RT, Langford C, Billingham L, Murray P, Deshmukh NS, et al. The West Midlands Bladder cancer prognosis programme: Rationale and design. *BJU Int* 2010;105:784–8. doi:10.1111/j.1464-410X.2009.08849.x.
- [10] Public Health England in association with the Welsh government, Food Standards Scotland and the Food Standards Agency in Northern Ireland. *The Eatwell Guide*. n.d.
- [11] Taylor JA, Kuchel GA. Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction. *Nat Clin Pract Urol* 2009;6:135–44. doi:10.1038/ncpuro1315.
- [12] Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, et al. Impact of gender on bladder cancer incidence, staging, and prognosis. *World J Urol* 2011;29:457–63. doi:10.1007/s00345-011-0709-9.
- [13] Wyszynski A, Tanyos SA, Rees JR, Marsit CJ, Kelsey KT, Schned AR, et al. Body mass and smoking are modifiable risk factors for recurrent bladder cancer. *Cancer* 2014;120:408–14. doi:10.1002/cncr.28394.
- [14] Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. *J Urol* 1998;160:645–59.
- [15] Yan Y, Andriole GL, Humphrey PA, Kibel AS. Patterns of multiple recurrences of superficial (Ta/T1) transitional cell carcinoma of bladder and effects of clinicopathologic and biochemical factors. *Cancer* 2002;95:1239–46. doi:10.1002/cncr.10822.

- [16] Ather MH, Nazim SM. New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer. *Korean J Urol* 2015;56:553. doi:10.4111/kju.2015.56.8.553.
- [17] Amorim LDAF, Cai J. Modelling recurrent events: A tutorial for analysis in epidemiology. *Int J Epidemiol* 2015;44:324–33. doi:10.1093/ije/dyu222.
- [18] D. Schoenfeld. Partial Residuals for The Proportionnal Hazards Regression Model. *Biometrika* 1982;69:239–41.
- [19] Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med* 1999;18:695–706.
- [20] Di Maso M, Bosetti C, Taborelli M, Montella M, Libra M, Zucchetto A, et al. Dietary water intake and bladder cancer risk: An Italian case–control study. *Cancer Epidemiol* 2016;45:151–6. doi:10.1016/j.canep.2016.09.015.
- [21] Liu Q, Liao B, Tian Y, Chen Y, Luo D, Lin Y, et al. Total fluid consumption and risk of bladder cancer: a meta-analysis with updated data. *Oncotarget* 2017;8:55467–77. doi:10.18632/oncotarget.18100.
- [22] Prasad S, Phromnoi K, Yadav V, Chaturvedi M, Aggarwal B. Targeting Inflammatory Pathways by Flavonoids for Prevention and Treatment of Cancer. *Planta Med* 2010;76:1044–63. doi:10.1055/s-0030-1250111.
- [23] Kim YS, Farrar W, Colburn NH, Milner JA. Cancer stem cells: potential target for bioactive food components. *J Nutr Biochem* 2012;23:691–8. doi:10.1016/j.jnutbio.2012.03.002.

- [24] Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, et al. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. *Cancer Res* 1998;58:5835–41.
- [25] Simon R, Eltze E, Schäfer KL, Bürger H, Semjonow A, Hertle L, et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. *Cancer Res* 2001;61:355–62.
- [26] Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng K, Wallace DMA, et al. Mechanisms of recurrence of Ta/T1 bladder cancer. *Ann R Coll Surg Engl* 2010;92:519–24. doi:10.1308/003588410X12664192076935.

SUPPLEMENTARY DATA ‘Total fluid intake and the risk of recurrence in patients with non-muscle invasive bladder cancer: a prospective cohort study’

Pre-diagnosis analysis

Table S1. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first recurrence of bladder cancer, based on total alcohol and beverage-specific alcohol intake 1 year before diagnosis (n=716)

			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	p trend
Total alcohol*									0.93
T1 (0 mL/day)	176	60	ref	.	ref	.	ref	.	
T2 (25 mL-125 mL/day)	231	75	0.91 (0.65-1.28)	0.60	0.94 (0.67-1.32)	0.72	0.90 (0.63-1.27)	0.55	
T3 (>125 mL/day)	306	102	0.95 (0.69-1.30)	0.74	1.00 (0.72-1.40)	0.98	0.97 (0.70-1.36)	0.87	
Beer (e.g. beer, lager, stout)									
Never/less than 1 per month	316	108	ref	.	ref	.	ref	.	0.56
1-3 per month	92	26	0.77 (0.50-1.18)	0.23	0.83 (0.53-1.28)	0.40	0.81 (0.52-1.27)	0.36	
1 per week	68	31	1.38 (0.91-2.08)	0.13	1.46 (0.95-2.24)	0.08	1.41 (0.92-2.15)	0.11	
2-4 per week	141	42	0.82 (0.58-1.17)	0.27	0.87 (0.61-1.25)	0.46	0.88 (0.61-1.27)	0.50	
5-6 per week	44	14	0.89 (0.52-1.51)	0.66	0.95 (0.55-1.63)	0.84	0.78 (0.45-1.35)	0.37	
At least 1 per day	55	16	0.85 (0.50-1.45)	0.55	0.90 (0.52-1.55)	0.69	0.93 (0.54-1.58)	0.78	
Cider									
Never/less than 1 per month	667	215	ref	.	ref	.	ref	.	0.26
1-3 per month	28	14	2.11 (1.26-3.54)	0.00	2.29 (1.40-3.76)	0.00	1.96 (1.15-3.37)	0.01	
1 per week	11	5	1.36 (0.58-3.17)	0.48	1.31 (0.58-2.98)	0.51	1.17 (0.57-2.38)	0.67	
2-4 per week	5	2	1.66 (0.32-8.62)	0.54	2.07 (0.40-10.81)	0.39	2.38 (0.49-11.51)	0.28	
5-6 per week	1	0	-	.	-	.	-	.	
At least 1 per day	4	1	0.65 (0.09-4.65)	0.67	0.68 (0.10-4.81)	0.70	0.90 (0.16-5.25)	0.91	
Wine or champagne									
Never/less than 1 per month	412	133	ref	.	ref	.	ref	.	0.32
1-3 per month	74	21	0.84 (0.54-1.32)	0.45	0.87 (0.56-1.37)	0.55	0.84 (0.53-1.34)	0.47	
1 per week	55	20	1.19 (0.71-1.98)	0.52	1.25 (0.74-2.11)	0.41	1.38 (0.82-2.30)	0.22	
2-4 per week	89	29	0.92 (0.62-1.38)	0.69	0.95 (0.63-1.41)	0.78	0.98 (0.65-1.46)	0.91	
5-6 per week	36	14	1.25 (0.71-2.21)	0.43	1.25 (0.72-2.17)	0.43	1.21 (0.69-2.11)	0.50	
At least 1 per day	50	20	1.19 (0.75-1.88)	0.46	1.18 (0.75-1.86)	0.47	1.25 (0.78-2.01)	0.36	

*Q1 includes non-drinkers only, Q2 includes drinkers whose consumption corresponds with up to 1 large glass of wine or half a pint of beer/lager per day, Q3 includes drinkers whose consumption corresponds with more than 1 large glass of wine or half a pint of beer/cider per day.

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S1. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	p trend
Fortified wine (e.g. port, sherry, cinzano)									
Never/less than 1 per month	625	208	ref	.	ref	.	ref	.	0.54
1-3 per month	49	13	0.70 (0.41-1.22)	0.21	0.70 (0.41-1.19)	0.19	0.70 (0.41-1.18)	0.18	
1 per week	20	6	0.80 (0.37-1.76)	0.59	0.73 (0.33-1.60)	0.43	0.81 (0.38-1.74)	0.59	
2-4 per week	12	5	1.27 (0.55-2.94)	0.58	1.31 (0.59-2.92)	0.50	1.52 (0.66-3.50)	0.32	
5-6 per week	6	3	1.85 (0.60-5.74)	0.29	1.70 (0.60-4.81)	0.32	1.40 (0.51-3.84)	0.51	
At least 1 per day	4	2	1.99 (0.34-11.59)	0.44	2.09 (0.36-12.19)	0.41	2.49 (0.45-13.72)	0.29	
Spirits (e.g. gin, brandy, rum, vodka, whiskey)									
Never/less than 1 per month	455	140	ref	.	ref	.	ref	.	0.88
1-3 per month	91	38	1.34 (0.93-1.93)	0.12	1.42 (0.98-2.05)	0.06	1.42 (0.98-2.06)	0.06	
1 per week	53	23	1.50 (0.98-2.30)	0.06	1.50 (0.99-2.29)	0.06	1.58 (1.03-2.43)	0.04	
2-4 per week	66	21	1.00 (0.64-1.58)	1.00	1.03 (0.65-1.62)	0.91	1.08 (0.68-1.72)	0.74	
5-6 per week	15	5	1.11 (0.46-2.69)	0.81	1.06 (0.44-2.55)	0.90	1.01 (0.40-2.60)	0.98	
At least 1 per day	36	10	0.86 (0.46-1.63)	0.65	0.83 (0.44-1.56)	0.57	0.80 (0.43-1.48)	0.47	
Liqueurs (e.g. tia maria, baileys, cointreau)									
Never/less than 1 per month	671	220	ref	.	ref	.	ref	.	0.05
1-3 per month	31	9	0.83 (0.43-1.63)	0.59	0.83 (0.43-1.62)	0.59	0.77 (0.39-1.52)	0.45	
1 per week	6	2	0.93 (0.22-3.91)	0.92	0.89 (0.21-3.68)	0.87	0.85 (0.21-3.43)	0.81	
2-4 per week	5	3	2.45 (0.67-9.02)	0.18	2.16 (0.58-8.09)	0.25	1.73 (0.46-6.46)	0.42	
5-6 per week	0	0	-	.	-	.	-	.	
At least 1 per day	3	3	4.76 (2.63-8.62)	0.00	4.72 (2.75-8.11)	0.00	6.66 (4.56-9.74)	0.00	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S2. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting multiple recurrences of bladder cancer, based on total alcohol and beverage-specific alcohol intake 1 year before diagnosis (n=716)

			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	p trend
Total alcohol*									
T1 (0 mL/day)	176	145	ref	.	ref	.	ref	.	0.87
T2 (25 mL-125 mL/day)	231	204	0.89 (0.77-1.02)	0.10	0.89 (0.77-1.03)	0.11	0.88 (0.77-1.02)	0.08	
T3 (>125 mL/day)	306	265	0.98 (0.87-1.11)	0.75	0.99 (0.86-1.13)	0.83	0.97 (0.84-1.11)	0.66	
Beer (e.g. beer, lager, stout)									
Never/less than 1 per month	316	166	ref	.	ref	.	ref	.	0.52
1-3 per month	92	38	0.97 (0.79-1.19)	0.76	0.98 (0.79-1.21)	0.83	0.96 (0.78-1.19)	0.73	
1 per week	68	63	1.03 (0.88-1.22)	0.69	1.04 (0.87-1.25)	0.65	1.05 (0.88-1.24)	0.61	
2-4 per week	141	58	1.08 (0.94-1.24)	0.28	1.09 (0.93-1.28)	0.27	1.08 (0.93-1.26)	0.31	
5-6 per week	44	27	0.97 (0.79-1.20)	0.80	0.99 (0.78-1.24)	0.90	0.88 (0.69-1.14)	0.33	
At least 1 per day	55	32	1.12 (0.92-1.35)	0.26	1.11 (0.90-1.37)	0.32	1.09 (0.88-1.37)	0.42	
Cider									
Never/less than 1 per month	667	348	ref	.	ref	.	ref	.	0.25
1-3 per month	28	22	1.04 (0.85-1.26)	0.70	1.03 (0.85-1.25)	0.76	1.00 (0.82-1.23)	0.98	
1 per week	11	10	0.88 (0.63-1.22)	0.44	0.87 (0.65-1.17)	0.37	0.87 (0.68-1.12)	0.29	
2-4 per week	5	3	3.27 (1.61-6.63)	0.00	3.34 (1.72-6.48)	0.00	3.64 (1.90-6.97)	0.00	
5-6 per week	1	0	-	.	-	.	-	.	
At least 1 per day	4	1	2.45 (2.02-2.98)	0.00	2.56 (2.11-3.12)	0.00	2.76 (2.19-3.46)	0.00	
Wine or champagne									
Never/less than 1 per month	412	210	ref	.	ref	.	ref	.	0.91
1-3 per month	74	33	1.15 (0.91-1.45)	0.25	1.15 (0.91-1.46)	0.24	1.18 (0.94-1.48)	0.17	
1 per week	55	26	1.35 (1.03-1.76)	0.03	1.35 (1.04-1.75)	0.03	1.29 (0.97-1.71)	0.08	
2-4 per week	89	49	1.03 (0.88-1.22)	0.69	1.03 (0.87-1.21)	0.75	1.01 (0.86-1.18)	0.90	
5-6 per week	36	33	0.84 (0.67-1.06)	0.14	0.86 (0.69-1.08)	0.19	0.89 (0.71-1.12)	0.33	
At least 1 per day	50	33	1.03 (0.87-1.23)	0.74	1.02 (0.86-1.21)	0.83	1.03 (0.86-1.22)	0.78	

*Q1 includes non-drinkers only, Q2 includes drinkers whose consumption corresponds with up to 1 large glass of wine or half a pint of beer/lager per day, Q3 includes drinkers whose consumption corresponds with more than 1 large glass of wine or half a pint of beer/cider per day.

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Table S2. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	HR (95% C.I.)	p-value	p trend
Fortified wine (e.g. port, sherry, cinzano)									
Never/less than 1 per month	625	334	ref	.	ref	.	ref	.	0.48
1-3 per month	49	20	1.05 (0.81-1.37)	0.71	1.06 (0.82-1.37)	0.67	1.06 (0.83-1.35)	0.64	
1 per week	20	11	0.85 (0.56-1.30)	0.45	0.87 (0.57-1.34)	0.53	0.88 (0.58-1.35)	0.56	
2-4 per week	12	11	0.85 (0.65-1.12)	0.25	0.83 (0.65-1.06)	0.13	0.83 (0.70-0.99)	0.04	
5-6 per week	6	6	0.92 (0.78-1.08)	0.30	0.91 (0.77-1.08)	0.29	0.93 (0.73-1.18)	0.55	
At least 1 per day	4	2	1.54 (0.93-2.54)	0.09	1.54 (0.98-2.44)	0.06	1.52 (0.90-2.58)	0.12	
Spirits (e.g. gin, brandy, rum, vodka, whiskey)									
Never/less than 1 per month	455	218	ref	.	ref	.	ref	.	0.45
1-3 per month	91	73	0.94 (0.81-1.09)	0.40	0.93 (0.79-1.08)	0.34	0.91 (0.78-1.06)	0.23	
1 per week	53	42	0.97 (0.82-1.15)	0.75	0.97 (0.82-1.15)	0.70	1.00 (0.84-1.18)	0.96	
2-4 per week	66	28	1.00 (0.80-1.25)	0.99	1.01 (0.80-1.26)	0.96	0.98 (0.76-1.25)	0.84	
5-6 per week	15	8	1.17 (0.88-1.55)	0.29	1.19 (0.89-1.59)	0.25	1.25 (0.99-1.58)	0.06	
At least 1 per day	36	15	1.18 (0.87-1.60)	0.28	1.17 (0.87-1.58)	0.31	1.18 (0.87-1.59)	0.29	
Liqueurs (e.g. tia maria, baileys, cointreau)									
Never/less than 1 per month	671	355	ref	.	ref	.	ref	.	0.67
1-3 per month	31	13	1.08 (0.78-1.49)	0.65	1.07 (0.77-1.50)	0.68	0.96 (0.64-1.42)	0.82	
1 per week	6	7	0.89 (0.61-1.29)	0.53	0.88 (0.59-1.30)	0.51	0.82 (0.56-1.22)	0.34	
2-4 per week	5	5	1.18 (0.75-1.85)	0.47	1.21 (0.74-1.99)	0.44	1.22 (0.74-2.00)	0.44	
5-6 per week	0	0	-	.	-	.	-	.	
At least 1 per day	3	4	0.82 (0.60-1.11)	0.19	0.80 (0.57-1.12)	0.19	0.89 (0.64-1.23)	0.47	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Table S3. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first recurrence of bladder cancer, based on non-alcoholic beverage intake 1 year before diagnosis (n=716)

			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% C.I.)	p-value	HR (95% CI)	p-value	HR (95% C.I.)	p-value	p trend
Coffee									
Never/less than 1 per month	152	39	ref	.	ref	.	ref	.	0.16
1-3 per month	39	15	1.60 (0.88-2.91)	0.12	1.79 (0.99-3.22)	0.05	1.84 (1.00-3.38)	0.05	
1 per week	46	14	1.13 (0.63-2.04)	0.68	1.19 (0.65-2.17)	0.58	1.03 (0.54-1.96)	0.94	
2-4 per week	78	27	1.35 (0.83-2.22)	0.23	1.36 (0.83-2.24)	0.22	1.34 (0.81-2.21)	0.26	
5-6 per week	34	13	1.43 (0.75-2.70)	0.27	1.58 (0.83-3.00)	0.16	1.46 (0.77-2.75)	0.25	
At least 1 per day	367	129	1.32 (0.92-1.88)	0.13	1.36 (0.94-1.96)	0.10	1.37 (0.94-2.00)	0.10	
Tea									
Never/less than 1 per month	73	21	ref	.	ref	.	ref	.	0.54
1-3 per month	11	4	1.60 (0.54-4.72)	0.39	1.58 (0.53-4.66)	0.41	1.34 (0.43-4.14)	0.61	
1 per week	1	0	-	.	-	.	-	.	
2-4 per week	13	7	2.17 (0.99-4.77)	0.05	2.13 (0.96-4.74)	0.06	2.10 (0.92-4.76)	0.08	
5-6 per week	24	11	1.83 (0.91-3.70)	0.09	1.81 (0.89-3.67)	0.10	1.58 (0.78-3.20)	0.20	
At least 1 per day	594	194	1.23 (0.81-1.87)	0.32	1.18 (0.77-1.79)	0.45	1.21 (0.80-1.83)	0.37	
Hot chocolate									
Never/less than 1 per month	548	179	ref	.	ref	.	ref	.	0.73
1-3 per month	70	24	1.16 (0.76-1.77)	0.50	1.19 (0.78-1.81)	0.42	1.05 (0.68-1.61)	0.84	
1 per week	26	7	0.74 (0.36-1.52)	0.42	0.75 (0.37-1.54)	0.44	0.74 (0.35-1.58)	0.44	
2-4 per week	29	13	1.43 (0.83-2.46)	0.20	1.39 (0.82-2.38)	0.23	1.16 (0.68-2.00)	0.58	
5-6 per week	4	0	-	.	-	.	-	.	
At least 1 per day	39	14	1.22 (0.68-2.17)	0.50	1.15 (0.64-2.07)	0.64	1.26 (0.70-2.25)	0.44	
Ovaltine / Horlicks									
Never/less than 1 per month	634	212	ref	.	ref	.	ref	.	0.51
1-3 per month	21	5	0.61 (0.26-1.39)	0.24	0.61 (0.27-1.39)	0.24	0.61 (0.26-1.47)	0.27	
1 per week	12	4	1.10 (0.38-3.22)	0.86	1.09 (0.38-3.11)	0.87	1.02 (0.35-2.95)	0.97	
2-4 per week	16	7	1.38 (0.66-2.87)	0.39	1.27 (0.61-2.64)	0.52	1.19 (0.57-2.48)	0.65	
5-6 per week	6	2	1.06 (0.28-4.02)	0.93	1.10 (0.29-4.22)	0.89	1.29 (0.33-5.02)	0.71	
At least 1 per day	27	7	0.66 (0.31-1.41)	0.28	0.64 (0.30-1.37)	0.25	0.70 (0.32-1.50)	0.36	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S3. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Soup									
Never/less than 1 per month	219	70	ref	.	ref	.	ref	.	0.13
1-3 per month	167	66	1.27 (0.91-1.78)	0.16	1.27 (0.91-1.78)	0.16	1.27 (0.91-1.78)	0.17	
1 per week	141	47	1.07 (0.74-1.55)	0.70	1.02 (0.71-1.48)	0.91	1.02 (0.70-1.48)	0.91	
2-4 per week	148	47	1.07 (0.74-1.55)	0.71	1.03 (0.71-1.50)	0.88	1.03 (0.71-1.51)	0.86	
5-6 per week	18	3	0.49 (0.15-1.56)	0.23	0.46 (0.14-1.47)	0.19	0.44 (0.13-1.49)	0.19	
At least 1 per day	23	4	0.47 (0.17-1.32)	0.15	0.44 (0.16-1.22)	0.11	0.44 (0.17-1.15)	0.09	
Fizzy pop (e.g. lemonade, cola)									
Never/less than 1 per month	437	154	ref	.	ref	.	ref	.	0.49
1-3 per month	71	23	1.00 (0.64-1.57)	1.00	1.05 (0.67-1.65)	0.83	1.06 (0.67-1.67)	0.82	
1 per week	55	14	0.66 (0.39-1.13)	0.13	0.70 (0.41-1.20)	0.19	0.69 (0.41-1.17)	0.17	
2-4 per week	68	19	0.79 (0.49-1.28)	0.34	0.82 (0.51-1.33)	0.43	0.81 (0.50-1.31)	0.40	
5-6 per week	14	2	0.33 (0.08-1.35)	0.12	0.33 (0.08-1.32)	0.12	0.34 (0.08-1.47)	0.15	
At least 1 per day	71	25	1.03 (0.68-1.57)	0.88	1.05 (0.69-1.61)	0.81	1.08 (0.70-1.65)	0.73	
Pure fruit juice (e.g. orange, apple)									
Never/less than 1 per month	275	86	ref	.	ref	.	ref	.	0.38
1-3 per month	82	33	1.38 (0.94-2.03)	0.10	1.43 (0.97-2.11)	0.07	1.54 (1.05-2.26)	0.03	
1 per week	72	21	1.02 (0.62-1.66)	0.94	1.11 (0.67-1.81)	0.69	1.09 (0.67-1.78)	0.72	
2-4 per week	103	27	0.80 (0.52-1.24)	0.32	0.87 (0.56-1.35)	0.52	0.90 (0.57-1.40)	0.63	
5-6 per week	42	20	1.68 (1.01-2.80)	0.05	1.71 (1.03-2.84)	0.04	1.76 (1.04-2.98)	0.03	
At least 1 per day	142	50	1.14 (0.81-1.61)	0.45	1.15 (0.81-1.62)	0.43	1.18 (0.83-1.67)	0.35	
Fruit squash or cordial									
Never/less than 1 per month	390	129	ref	.	ref	.	ref	.	0.81
1-3 per month	60	19	0.92 (0.57-1.48)	0.72	0.91 (0.57-1.48)	0.71	1.04 (0.64-1.71)	0.87	
1 per week	64	17	0.80 (0.48-1.32)	0.39	0.82 (0.49-1.36)	0.43	0.83 (0.51-1.36)	0.46	
2-4 per week	72	25	1.04 (0.68-1.59)	0.86	1.06 (0.69-1.63)	0.78	1.03 (0.67-1.59)	0.90	
5-6 per week	29	10	1.01 (0.54-1.90)	0.97	1.03 (0.54-1.96)	0.93	1.10 (0.58-2.10)	0.77	
At least 1 per day	101	37	1.14 (0.79-1.64)	0.49	1.12 (0.77-1.61)	0.56	1.05 (0.73-1.51)	0.79	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S3. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Milk									
Never/less than 1 per month	432	148	ref	.	ref	.	ref	.	0.37
1-3 per month	51	16	0.79 (0.49-1.29)	0.35	0.82 (0.50-1.35)	0.44	0.77 (0.47-1.27)	0.31	
1 per week	31	11	1.03 (0.56-1.92)	0.92	1.05 (0.56-1.96)	0.88	0.97 (0.53-1.78)	0.92	
2-4 per week	50	19	1.09 (0.68-1.74)	0.73	1.18 (0.73-1.90)	0.50	1.29 (0.80-2.08)	0.29	
5-6 per week	27	7	0.64 (0.30-1.39)	0.26	0.68 (0.32-1.44)	0.31	0.68 (0.32-1.45)	0.31	
At least 1 per day	125	36	0.79 (0.55-1.14)	0.21	0.80 (0.56-1.16)	0.24	0.83 (0.57-1.20)	0.31	
Water (tap, filtered, or bottled)									
Never/less than 1 per month	86	35	ref	.	ref	.	ref	.	0.18
1-3 per month	25	8	0.83 (0.40-1.75)	0.63	0.86 (0.41-1.82)	0.69	0.83 (0.39-1.74)	0.62	
1 per week	33	11	0.80 (0.41-1.58)	0.53	0.82 (0.42-1.62)	0.56	0.77 (0.39-1.52)	0.45	
2-4 per week	47	17	0.92 (0.52-1.64)	0.78	0.97 (0.54-1.73)	0.91	0.83 (0.46-1.49)	0.53	
5-6 per week	51	14	0.73 (0.38-1.40)	0.34	0.79 (0.41-1.53)	0.49	0.80 (0.42-1.56)	0.52	
At least 1 per day	474	152	0.76 (0.53-1.09)	0.14	0.78 (0.54-1.14)	0.20	0.76 (0.52-1.10)	0.14	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, tumour stage, grade, size and multiplicity.

Table S4. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting multiple recurrences of bladder cancer, based on non-alcoholic beverage intake 1 year before diagnosis (n=716)

			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Coffee									
Never/less than 1 per month	152	50	ref	.	ref	.	ref	.	0.52
1-3 per month	39	25	1.00 (0.83-1.21)	0.96	1.01 (0.84-1.21)	0.91	0.99 (0.83-1.19)	0.93	
1 per week	46	26	1.11 (0.81-1.52)	0.52	1.09 (0.79-1.50)	0.59	1.08 (0.78-1.50)	0.63	
2-4 per week	78	53	1.03 (0.87-1.23)	0.69	1.05 (0.88-1.25)	0.59	1.06 (0.88-1.26)	0.55	
5-6 per week	34	21	0.99 (0.74-1.31)	0.92	1.01 (0.76-1.34)	0.93	1.00 (0.76-1.33)	0.99	
At least 1 per day	367	209	0.99 (0.86-1.14)	0.89	0.99 (0.86-1.14)	0.93	0.98 (0.84-1.13)	0.73	
Tea									
Never/less than 1 per month	73	34	ref	.	ref	.	ref	.	0.82
1-3 per month	11	7	1.65 (0.75-3.62)	0.21	1.73 (0.83-3.60)	0.14	1.61 (0.81-3.23)	0.18	
1 per week	1	0	-	.	-	.	-	.	
2-4 per week	13	15	1.14 (0.79-1.64)	0.50	1.16 (0.79-1.69)	0.44	1.11 (0.78-1.59)	0.56	
5-6 per week	24	17	1.05 (0.76-1.46)	0.76	1.08 (0.78-1.51)	0.63	1.02 (0.74-1.42)	0.89	
At least 1 per day	594	311	1.14 (0.90-1.45)	0.28	1.14 (0.90-1.45)	0.29	1.09 (0.86-1.38)	0.47	
Hot chocolate									
Never/less than 1 per month	548	284	ref	.	ref	.	ref	.	0.74
1-3 per month	70	39	0.89 (0.77-1.04)	0.15	0.88 (0.75-1.03)	0.10	0.87 (0.74-1.02)	0.09	
1 per week	26	15	0.87 (0.70-1.07)	0.18	0.87 (0.70-1.08)	0.20	0.89 (0.73-1.10)	0.29	
2-4 per week	29	25	1.01 (0.80-1.29)	0.91	1.01 (0.78-1.29)	0.96	0.98 (0.76-1.27)	0.86	
5-6 per week	4	0	-	.	-	.	-	.	
At least 1 per day	39	21	1.07 (0.87-1.31)	0.52	1.06 (0.87-1.30)	0.58	1.01 (0.82-1.24)	0.94	
Ovaltine / horlicks									
Never/less than 1 per month	634	343	ref	.	ref	.	ref	.	0.25
1-3 per month	21	5	0.78 (0.66-0.92)	0.00	0.78 (0.67-0.91)	0.00	0.77 (0.67-0.89)	0.00	
1 per week	12	6	1.64 (0.82-3.25)	0.16	1.68 (0.83-3.38)	0.15	1.79 (0.87-3.67)	0.11	
2-4 per week	16	13	0.97 (0.78-1.22)	0.81	0.98 (0.78-1.24)	0.88	1.02 (0.82-1.26)	0.88	
5-6 per week	6	5	1.65 (1.32-2.06)	0.00	1.64 (1.32-2.03)	0.00	1.74 (1.41-2.15)	0.00	
At least 1 per day	27	12	1.10 (0.89-1.36)	0.39	1.03 (0.81-1.31)	0.80	0.98 (0.75-1.29)	0.89	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Table S4. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Soup									
Never/less than 1 per month	219	113	ref	.	ref	.	ref	.	0.37
1-3 per month	167	108	0.99 (0.86-1.15)	0.93	1.00 (0.86-1.16)	0.99	1.00 (0.86-1.16)	0.97	
1 per week	141	78	0.97 (0.85-1.12)	0.72	0.98 (0.85-1.14)	0.81	0.97 (0.84-1.12)	0.69	
2-4 per week	148	69	1.10 (0.93-1.29)	0.27	1.09 (0.92-1.29)	0.30	1.08 (0.92-1.27)	0.34	
5-6 per week	18	10	0.79 (0.64-0.97)	0.03	0.79 (0.64-0.99)	0.04	0.85 (0.67-1.07)	0.16	
At least 1 per day	23	6	1.70 (0.94-3.09)	0.08	1.68 (0.94-3.00)	0.08	1.63 (0.97-2.74)	0.07	
Fizzy pop (e.g. lemonade, cola)									
Never/less than 1 per month	437	246	ref	.	ref	.	ref	.	0.33
1-3 per month	71	38	0.94 (0.78-1.15)	0.57	0.96 (0.79-1.17)	0.68	0.96 (0.80-1.16)	0.68	
1 per week	55	24	1.03 (0.86-1.22)	0.76	1.04 (0.87-1.24)	0.70	1.02 (0.85-1.22)	0.83	
2-4 per week	68	34	1.01 (0.85-1.19)	0.93	1.03 (0.87-1.22)	0.73	1.05 (0.88-1.26)	0.58	
5-6 per week	14	2	0.78 (0.68-0.90)	0.00	0.84 (0.71-0.99)	0.04	0.79 (0.64-0.98)	0.03	
At least 1 per day	71	40	1.11 (0.92-1.33)	0.29	1.11 (0.93-1.33)	0.25	1.09 (0.91-1.31)	0.33	
Pure fruit juice (e.g. orange, apple)									
Never/less than 1 per month	275	142	ref	.	ref	.	ref	.	0.43
1-3 per month	82	53	0.93 (0.79-1.09)	0.39	0.92 (0.78-1.08)	0.32	0.95 (0.81-1.11)	0.51	
1 per week	72	36	1.02 (0.83-1.24)	0.88	1.01 (0.83-1.24)	0.89	1.00 (0.82-1.22)	0.98	
2-4 per week	103	35	1.09 (0.90-1.33)	0.37	1.12 (0.92-1.36)	0.27	1.12 (0.91-1.37)	0.29	
5-6 per week	42	39	0.91 (0.75-1.11)	0.36	0.90 (0.73-1.11)	0.32	0.94 (0.76-1.15)	0.55	
At least 1 per day	142	79	0.91 (0.78-1.06)	0.21	0.90 (0.78-1.05)	0.18	0.92 (0.80-1.06)	0.27	
Fruit squash or cordial									
Never/less than 1 per month	390	213	ref	.	ref	.	ref	.	0.39
1-3 per month	60	29	0.93 (0.76-1.14)	0.49	0.91 (0.75-1.11)	0.35	0.92 (0.77-1.11)	0.40	
1 per week	64	18	1.19 (0.92-1.52)	0.18	1.16 (0.90-1.50)	0.24	1.13 (0.87-1.47)	0.36	
2-4 per week	72	40	1.01 (0.86-1.19)	0.87	1.00 (0.85-1.19)	0.97	0.97 (0.82-1.16)	0.75	
5-6 per week	29	21	1.02 (0.78-1.33)	0.90	1.04 (0.78-1.38)	0.79	1.04 (0.79-1.37)	0.79	
At least 1 per day	101	63	1.10 (0.93-1.29)	0.27	1.08 (0.92-1.27)	0.34	1.08 (0.92-1.26)	0.35	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Table S4. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Milk									
Never/less than 1 per month	432	241	ref	.	ref	.	ref	.	0.25
1-3 per month	51	20	0.92 (0.79-1.07)	0.30	0.94 (0.81-1.09)	0.42	0.97 (0.83-1.12)	0.66	
1 per week	31	21	1.13 (0.88-1.45)	0.33	1.13 (0.87-1.47)	0.37	1.14 (0.86-1.50)	0.36	
2-4 per week	50	36	0.80 (0.71-0.91)	0.00	0.80 (0.70-0.92)	0.00	0.79 (0.68-0.92)	0.00	
5-6 per week	27	20	0.87 (0.66-1.14)	0.30	0.89 (0.66-1.19)	0.43	0.92 (0.68-1.24)	0.58	
At least 1 per day	125	46	1.01 (0.87-1.17)	0.90	1.00 (0.86-1.16)	1.00	0.98 (0.85-1.14)	0.83	
Water (tap, filtered, or bottled)									
Never/less than 1 per month	86	49	ref	.	ref	.	ref	.	0.33
1-3 per month	25	14	0.80 (0.67-0.96)	0.02	0.83 (0.68-1.00)	0.05	0.86 (0.71-1.03)	0.10	
1 per week	33	21	0.69 (0.53-0.89)	0.00	0.68 (0.52-0.89)	0.01	0.71 (0.55-0.91)	0.01	
2-4 per week	47	35	0.97 (0.79-1.19)	0.75	0.97 (0.79-1.20)	0.81	0.98 (0.79-1.22)	0.89	
5-6 per week	51	35	0.91 (0.72-1.14)	0.40	0.93 (0.73-1.17)	0.54	0.94 (0.74-1.19)	0.61	
At least 1 per day	474	230	0.99 (0.83-1.17)	0.89	1.00 (0.84-1.18)	0.96	1.01 (0.85-1.20)	0.91	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Post-diagnosis analysis

Table S5. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first recurrence of bladder cancer, based on total alcohol and beverage-specific alcohol intake 1 year after diagnosis (n=379)

			Model 1*		Model 2**		Model 3***		
	n	Events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Total alcohol*									
T1 (0 mL/day)	87	32	ref	.	ref	.	ref	.	0.94
T2 (25 mL-125 mL/day)	130	49	0.96 (0.62-1.50)	0.85	0.97 (0.62-1.51)	0.88	0.97 (0.62-1.51)	0.89	
T3 (>125 mL/day)	162	58	0.93 (0.61-1.44)	0.76	0.94 (0.60-1.47)	0.79	1.01 (0.65-1.58)	0.96	
Beer (e.g. beer, lager, stout)									
Never/less than 1 per month	169	65	ref	.	ref	.	ref	.	0.93
1-3 per month	39	14	0.86 (0.49-1.50)	0.58	0.82 (0.46-1.45)	0.49	0.94 (0.53-1.65)	0.82	
1 per week	43	15	0.86 (0.49-1.52)	0.60	0.90 (0.50-1.60)	0.71	1.00 (0.55-1.81)	0.99	
2-4 per week	60	21	0.87 (0.53-1.41)	0.57	0.84 (0.51-1.38)	0.48	1.00 (0.60-1.69)	0.99	
5-6 per week	24	6	0.58 (0.25-1.33)	0.20	0.56 (0.24-1.35)	0.20	0.65 (0.26-1.65)	0.37	
At least 1 per day	44	18	1.08 (0.64-1.82)	0.78	1.03 (0.59-1.79)	0.92	1.05 (0.60-1.84)	0.86	
Cider									
Never/less than 1 per month	356	129	ref	.	ref	.	ref	.	0.21
1-3 per month	15	7	1.45 (0.66-3.19)	0.35	1.60 (0.75-3.40)	0.23	1.43 (0.68-3.04)	0.35	
1 per week	3	0	-	.	-	.	-	.	
2-4 per week	3	2	2.54 (0.55-11.79)	0.23	2.86 (0.68-11.99)	0.15	4.57 (2.11-9.87)	0.00	
5-6 per week	1	1	4.28 (3.41-5.37)	0.00	3.91 (2.99-5.10)	0.00	5.70 (2.71-12.00)	0.00	
At least 1 per day	1	0	-	.	-	.	-	.	
Wine or champagne									
Never/less than 1 per month	202	75	ref	.	ref	.	ref	.	0.36
1-3 per month	27	8	0.78 (0.38-1.63)	0.51	0.87 (0.41-1.84)	0.72	0.80 (0.38-1.65)	0.54	
1 per week	37	15	1.14 (0.65-2.00)	0.66	1.19 (0.68-2.11)	0.54	1.11 (0.63-1.93)	0.72	
2-4 per week	61	18	0.76 (0.45-1.28)	0.30	0.81 (0.47-1.39)	0.45	0.89 (0.52-1.55)	0.69	
5-6 per week	12	6	1.38 (0.61-3.09)	0.44	1.46 (0.68-3.15)	0.33	1.89 (0.83-4.30)	0.13	
At least 1 per day	40	17	1.21 (0.71-2.07)	0.48	1.26 (0.74-2.13)	0.40	1.29 (0.74-2.24)	0.37	

*Q1 includes non-drinkers only, Q2 includes drinkers whose consumption corresponds with up to 1 large glass of wine or half a pint of beer/lager per day, Q3 includes drinkers whose consumption corresponds with more than 1 large glass of wine or half a pint of beer/cider per day.

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S5. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Fortified wine (e.g. port, sherry, cinzano)									
Never/less than 1 per month	339	124	ref	.	ref	.	ref	.	0.55
1-3 per month	23	11	1.38 (0.73-2.60)	0.33	1.42 (0.76-2.68)	0.28	1.53 (0.84-2.80)	0.16	
1 per week	10	2	0.49 (0.13-1.87)	0.30	0.53 (0.14-1.98)	0.35	0.52 (0.15-1.79)	0.30	
2-4 per week	5	2	0.86 (0.27-2.75)	0.80	0.91 (0.33-2.50)	0.85	0.83 (0.29-2.34)	0.72	
5-6 per week	1	0	-	.	-	.	-	.	
At least 1 per day	1	0	-	.	-	.	-	.	
Spirits (e.g. gin, brandy, rum, vodka, whiskey)									
Never/less than 1 per month	243	90	ref	.	ref	.	ref	.	0.39
1-3 per month	45	16	0.96 (0.55-1.68)	0.88	0.94 (0.54-1.64)	0.84	1.01 (0.58-1.76)	0.98	
1 per week	19	10	1.46 (0.78-2.71)	0.23	1.44 (0.77-2.72)	0.25	1.39 (0.75-2.58)	0.30	
2-4 per week	42	14	0.88 (0.50-1.53)	0.64	0.86 (0.49-1.49)	0.59	0.81 (0.46-1.44)	0.48	
5-6 per week	9	4	1.12 (0.47-2.66)	0.80	1.07 (0.43-2.67)	0.89	1.30 (0.49-3.41)	0.60	
At least 1 per day	21	5	0.59 (0.25-1.41)	0.24	0.56 (0.24-1.33)	0.19	0.59 (0.26-1.35)	0.21	
Liqueurs (e.g. tia maria, baileys, cointreau)									
Never/less than 1 per month	359	130	ref	.	ref	.	ref	.	0.82
1-3 per month	12	5	1.07 (0.48-2.39)	0.88	0.98 (0.45-2.17)	0.97	0.92 (0.40-2.14)	0.85	
1 per week	2	2	15.71 (5.23-47.15)	0.00	18.43 (5.62-60.43)	0.00	15.62 (4.21-58.01)	0.00	
2-4 per week	4	1	0.69 (0.09-5.36)	0.73	0.70 (0.09-5.24)	0.73	0.70 (0.12-4.18)	0.69	
5-6 per week	0	0	-		-		-		
At least 1 per day	2	1	1.42 (0.20-10.29)	0.73	1.21 (0.16-8.86)	0.85	0.94 (0.08-11.14)	0.96	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S6. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting multiple recurrences of bladder cancer, based on total alcohol and beverage-specific alcohol intake 1 year after diagnosis (n=379)

			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Total alcohol*									
T1 (0 mL/day)	87	79	ref	.	ref	.	ref	.	0.42
T2 (25 mL-125 mL/day)	130	124	0.91 (0.77-1.09)	0.31	0.90 (0.76-1.08)	0.26	0.93 (0.78-1.10)	0.38	
T3 (>125 mL/day)	162	142	1.06 (0.89-1.27)	0.50	1.03 (0.86-1.23)	0.75	1.05 (0.88-1.25)	0.60	
Beer (e.g. beer, lager, stout)									
Never/less than 1 per month	169	97	ref	.	ref	.	ref	.	0.09
1-3 per month	39	15	0.93 (0.79-1.10)	0.39	0.92 (0.75-1.13)	0.44	0.92 (0.74-1.15)	0.46	
1 per week	43	29	1.23 (0.97-1.56)	0.08	1.27 (0.99-1.64)	0.06	1.31 (1.03-1.65)	0.03	
2-4 per week	60	30	1.11 (0.92-1.34)	0.29	1.10 (0.89-1.36)	0.39	1.06 (0.88-1.29)	0.54	
5-6 per week	24	6	1.17 (0.79-1.73)	0.45	1.16 (0.77-1.74)	0.48	1.16 (0.74-1.82)	0.52	
At least 1 per day	44	36	1.18 (0.99-1.41)	0.07	1.16 (0.96-1.40)	0.13	1.16 (0.95-1.41)	0.16	
Cider									
Never/less than 1 per month	356	197	ref	.	ref	.	ref	.	0.94
1-3 per month	15	11	1.13 (0.88-1.44)	0.34	1.06 (0.80-1.40)	0.68	1.00 (0.75-1.33)	0.99	
1 per week	3	0	-		-		-		
2-4 per week	3	4	0.75 (0.51-1.09)	0.13	0.74 (0.50-1.08)	0.11	0.83 (0.56-1.23)	0.36	
5-6 per week	1	1	2.45 (1.93-3.10)	0.00	2.36 (1.85-3.01)	0.00	2.47 (1.53-3.96)	0.00	
At least 1 per day	1	0	-	.	-	.	-	.	
Wine or champagne									
Never/less than 1 per month	202	113	ref	.	ref	.	ref	.	0.35
1-3 per month	27	21	0.87 (0.69-1.10)	0.24	0.86 (0.69-1.08)	0.19	0.88 (0.71-1.09)	0.24	
1 per week	37	22	1.07 (0.91-1.27)	0.39	1.06 (0.90-1.25)	0.51	1.09 (0.90-1.31)	0.38	
2-4 per week	61	25	1.02 (0.82-1.28)	0.84	1.03 (0.82-1.29)	0.79	1.11 (0.89-1.39)	0.35	
5-6 per week	12	9	0.80 (0.54-1.18)	0.26	0.77 (0.53-1.12)	0.17	0.80 (0.55-1.18)	0.26	
At least 1 per day	40	23	1.16 (0.90-1.49)	0.25	1.17 (0.91-1.51)	0.22	1.16 (0.90-1.50)	0.26	

*Q1 includes non-drinkers only, Q2 includes drinkers whose consumption corresponds with up to 1 large glass of wine or half a pint of beer/lager per day, Q3 includes drinkers whose consumption corresponds with more than 1 large glass of wine or half a pint of beer/cider per day.

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Table S6. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Fortified wine (e.g. port, sherry, cinzano)									
Never/less than 1 per month	339	194	ref	.	ref	.	ref	.	0.35
1-3 per month	23	13	1.04 (0.80-1.35)	0.76	1.07 (0.83-1.39)	0.60	1.08 (0.84-1.38)	0.55	
1 per week	10	4	0.60 (0.36-1.01)	0.05	0.60 (0.36-1.03)	0.06	0.62 (0.36-1.07)	0.09	
2-4 per week	5	2	0.86 (0.64-1.14)	0.30	0.92 (0.63-1.35)	0.68	0.90 (0.63-1.30)	0.58	
5-6 per week	1	0	-	.	-	.	-	.	
At least 1 per day	1	0	-	.	-	.	-	.	
Spirits (e.g. gin, brandy, rum, vodka, whiskey)									
Never/less than 1 per month	243	142	ref	.	ref	.	ref	.	0.55
1-3 per month	45	34	0.94 (0.77-1.15)	0.54	0.93 (0.77-1.13)	0.49	0.92 (0.77-1.11)	0.41	
1 per week	19	11	0.99 (0.84-1.16)	0.87	1.02 (0.87-1.20)	0.82	0.95 (0.75-1.20)	0.66	
2-4 per week	42	15	1.07 (0.87-1.31)	0.53	1.10 (0.89-1.36)	0.39	1.08 (0.86-1.35)	0.52	
5-6 per week	9	6	1.14 (0.82-1.61)	0.43	1.10 (0.79-1.54)	0.57	1.13 (0.81-1.59)	0.48	
At least 1 per day	21	5	0.99 (0.67-1.46)	0.95	1.01 (0.67-1.53)	0.96	1.08 (0.70-1.68)	0.73	
Liqueurs (e.g. tia maria, baileys, cointreau)									
Never/less than 1 per month	359	202	ref	.	ref	.	ref	.	0.85
1-3 per month	12	5	0.88 (0.64-1.21)	0.44	0.92 (0.66-1.29)	0.64	0.90 (0.65-1.24)	0.52	
1 per week	2	3	1.06 (0.58-1.94)	0.84	1.11 (0.62-1.97)	0.73	0.93 (0.51-1.71)	0.82	
2-4 per week	4	2	1.03 (0.77-1.37)	0.84	1.06 (0.79-1.43)	0.70	1.10 (0.79-1.52)	0.57	
5-6 per week	0	0	-		-		-		
At least 1 per day	2	1	0.83 (0.75-0.92)	0.00	0.91 (0.76-1.08)	0.27	0.97 (0.79-1.17)	0.73	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Table S7. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting a first recurrence of bladder cancer, based on non-alcoholic beverage intake 1 year after diagnosis (n=379)

			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Coffee									
Never/less than 1 per month	80	23	ref	.	ref	.	ref	.	0.13
1-3 per month	20	7	1.30 (0.54-3.13)	0.55	1.33 (0.56-3.19)	0.52	1.02 (0.41-2.51)	0.97	
1 per week	24	9	1.40 (0.65-3.02)	0.39	1.51 (0.70-3.29)	0.29	1.39 (0.62-3.16)	0.43	
2-4 per week	31	13	1.57 (0.78-3.16)	0.21	1.59 (0.79-3.20)	0.19	1.55 (0.75-3.20)	0.24	
5-6 per week	6	2	1.21 (0.30-4.81)	0.79	1.29 (0.35-4.74)	0.71	0.87 (0.26-2.95)	0.83	
At least 1 per day	218	85	1.37 (0.86-2.19)	0.18	1.42 (0.89-2.27)	0.14	1.44 (0.89-2.31)	0.14	
Tea									
Never/less than 1 per month	37	15	ref	.	ref	.	ref	.	0.74
1-3 per month	1	0	-	.	-	.	-	.	
1 per week	7	3	1.29 (0.35-4.81)	0.70	1.43 (0.40-5.10)	0.58	1.87 (0.60-5.89)	0.28	
2-4 per week	13	7	1.42 (0.64-3.13)	0.39	1.74 (0.80-3.80)	0.16	2.03 (0.91-4.53)	0.08	
5-6 per week	8	3	1.01 (0.35-2.90)	0.99	1.10 (0.41-2.96)	0.85	1.11 (0.41-3.03)	0.84	
At least 1 per day	313	111	1.00 (0.61-1.64)	0.99	1.03 (0.63-1.69)	0.89	1.18 (0.71-1.97)	0.53	
Hot chocolate									
Never/less than 1 per month	311	115	ref	.	ref	.	ref	.	0.15
1-3 per month	22	10	1.32 (0.70-2.49)	0.40	1.36 (0.74-2.50)	0.32	1.11 (0.63-1.95)	0.72	
1 per week	17	5	0.74 (0.31-1.74)	0.49	0.76 (0.33-1.75)	0.51	0.55 (0.24-1.26)	0.16	
2-4 per week	15	6	1.07 (0.49-2.36)	0.86	1.06 (0.48-2.36)	0.88	0.86 (0.37-2.01)	0.73	
5-6 per week	0	0	-	.	-	.	-	.	
At least 1 per day	14	3	0.53 (0.17-1.63)	0.27	0.50 (0.16-1.59)	0.24	0.50 (0.15-1.62)	0.24	
Ovaltine / Horlicks									
Never/less than 1 per month	332	119	ref	.	ref	.	ref	.	0.67
1-3 per month	11	6	1.82 (0.80-4.15)	0.16	1.89 (0.84-4.22)	0.12	1.71 (0.78-3.76)	0.18	
1 per week	3	0	-	.	-	.	-	.	
2-4 per week	12	6	1.68 (0.75-3.75)	0.21	1.55 (0.69-3.46)	0.29	1.09 (0.48-2.51)	0.83	
5-6 per week	2	1	1.99 (0.20-20.10)	0.56	1.78 (0.18-18.07)	0.62	1.57 (0.15-16.70)	0.71	
At least 1 per day	19	7	1.05 (0.49-2.25)	0.89	1.11 (0.51-2.39)	0.80	1.13 (0.52-2.45)	0.76	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S7. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Soup									
Never/less than 1 per month	103	33	ref	.	ref	.	ref	.	0.59
1-3 per month	101	44	1.50 (0.96-2.34)	0.08	1.54 (0.98-2.42)	0.06	1.53 (0.97-2.39)	0.07	
1 per week	80	30	1.27 (0.77-2.09)	0.35	1.29 (0.78-2.12)	0.32	1.36 (0.81-2.27)	0.24	
2-4 per week	77	26	1.17 (0.69-1.97)	0.57	1.17 (0.68-1.99)	0.57	1.20 (0.70-2.08)	0.51	
5-6 per week	9	3	1.24 (0.35-4.44)	0.74	1.31 (0.38-4.52)	0.67	1.72 (0.53-5.60)	0.37	
At least 1 per day	9	3	1.05 (0.34-3.26)	0.94	1.11 (0.38-3.21)	0.85	1.01 (0.38-2.66)	0.98	
Fizzy pop (e.g. lemonade, cola)									
Never/less than 1 per month	251	95	ref	.	ref	.	ref	.	0.49
1-3 per month	23	6	0.62 (0.28-1.37)	0.24	0.62 (0.27-1.39)	0.25	0.53 (0.21-1.30)	0.17	
1 per week	23	9	1.05 (0.53-2.10)	0.88	1.02 (0.51-2.05)	0.96	0.80 (0.41-1.53)	0.50	
2-4 per week	38	14	0.97 (0.54-1.75)	0.92	0.97 (0.54-1.73)	0.92	0.96 (0.53-1.75)	0.90	
5-6 per week	10	3	0.77 (0.27-2.21)	0.62	0.73 (0.26-2.09)	0.56	0.82 (0.26-2.53)	0.72	
At least 1 per day	34	12	0.88 (0.50-1.54)	0.65	0.84 (0.48-1.50)	0.56	0.81 (0.45-1.47)	0.50	
Pure fruit juice (e.g. orange, apple)									
Never/less than 1 per month	144	44	ref	.	ref	.	ref	.	0.92
1-3 per month	33	21	2.28 (1.41-3.70)	0.00	2.25 (1.39-3.66)	0.00	2.21 (1.39-3.53)	0.00	
1 per week	38	18	1.73 (0.98-3.07)	0.06	1.76 (0.98-3.16)	0.06	1.88 (1.06-3.35)	0.03	
2-4 per week	55	19	1.09 (0.64-1.84)	0.76	1.07 (0.64-1.80)	0.78	1.10 (0.65-1.86)	0.71	
5-6 per week	3	1	1.02 (0.13-8.29)	0.98	1.13 (0.15-8.47)	0.91	0.91 (0.18-4.48)	0.91	
At least 1 per day	106	36	1.07 (0.69-1.68)	0.76	1.07 (0.68-1.68)	0.77	1.17 (0.73-1.86)	0.51	
Fruit squash or cordial									
Never/less than 1 per month	202	73	ref	.	ref	.	ref	.	0.35
1-3 per month	20	4	0.49 (0.18-1.33)	0.16	0.47 (0.17-1.30)	0.15	0.52 (0.20-1.36)	0.18	
1 per week	32	12	1.05 (0.56-1.97)	0.88	1.07 (0.58-2.00)	0.82	0.99 (0.55-1.81)	0.99	
2-4 per week	37	12	0.83 (0.45-1.51)	0.54	0.78 (0.43-1.43)	0.43	0.79 (0.44-1.43)	0.43	
5-6 per week	6	2	0.96 (0.23-4.04)	0.95	0.87 (0.20-3.73)	0.85	0.93 (0.21-4.21)	0.93	
At least 1 per day	82	36	1.19 (0.81-1.76)	0.38	1.21 (0.81-1.80)	0.36	1.26 (0.85-1.88)	0.25	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S7. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Milk									
Never/less than 1 per month	273	107	ref	.	ref	.	ref	.	0.39
1-3 per month	12	3	0.58 (0.20-1.72)	0.33	0.57 (0.19-1.71)	0.32	0.47 (0.17-1.31)	0.15	
1 per week	8	2	0.67 (0.15-3.01)	0.60	0.80 (0.17-3.72)	0.78	0.84 (0.17-4.21)	0.83	
2-4 per week	28	7	0.58 (0.27-1.22)	0.15	0.58 (0.28-1.22)	0.15	0.65 (0.31-1.38)	0.26	
5-6 per week	5	3	1.63 (0.70-3.80)	0.26	1.64 (0.73-3.68)	0.23	1.41 (0.56-3.57)	0.47	
At least 1 per day	53	17	0.80 (0.47-1.35)	0.40	0.81 (0.47-1.39)	0.44	0.81 (0.46-1.42)	0.45	
Water (tap, filtered, or bottled)									
Never/less than 1 per month	50	22	ref	.	ref	.	ref	.	0.27
1-3 per month	5	2	0.74 (0.18-3.06)	0.68	0.72 (0.16-3.23)	0.66	0.84 (0.21-3.34)	0.81	
1 per week	9	4	1.14 (0.36-3.62)	0.82	1.16 (0.36-3.72)	0.80	1.19 (0.47-3.06)	0.71	
2-4 per week	25	10	0.76 (0.37-1.58)	0.47	0.79 (0.38-1.65)	0.53	1.00 (0.47-2.14)	1.00	
5-6 per week	11	4	0.68 (0.26-1.78)	0.43	0.69 (0.27-1.77)	0.44	0.63 (0.26-1.48)	0.29	
At least 1 per day	279	97	0.70 (0.45-1.11)	0.13	0.75 (0.47-1.22)	0.25	0.79 (0.49-1.28)	0.34	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity.

Table S8. Hazard ratios (HR) and 95% confidence intervals (95% C.I.) for Cox proportional hazard models predicting multiple recurrences of bladder cancer, based on non-alcoholic beverage intake 1 year after diagnosis (n=379)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Coffee									
Never/less than 1 per month	80	33	ref	.	ref	.	ref	.	0.97
1-3 per month	20	14	0.96 (0.77-1.20)	0.72	0.94 (0.76-1.17)	0.57	0.96 (0.79-1.17)	0.70	
1 per week	24	13	1.15 (0.80-1.64)	0.44	1.10 (0.75-1.61)	0.64	1.02 (0.69-1.51)	0.92	
2-4 per week	31	23	0.98 (0.77-1.25)	0.87	0.99 (0.78-1.26)	0.95	1.03 (0.81-1.31)	0.83	
5-6 per week	6	4	0.88 (0.53-1.47)	0.63	0.92 (0.56-1.53)	0.75	0.79 (0.45-1.37)	0.40	
At least 1 per day	218	126	1.00 (0.85-1.19)	0.98	1.00 (0.85-1.18)	0.98	0.99 (0.83-1.17)	0.90	
Tea									
Never/less than 1 per month	37	22	ref	.	ref	.	ref	.	0.92
1-3 per month	1	0	-	.	-	.	-	.	
1 per week	7	7	1.47 (0.81-2.67)	0.20	1.47 (0.78-2.75)	0.23	1.31 (0.65-2.65)	0.45	
2-4 per week	13	8	1.28 (0.88-1.85)	0.20	1.24 (0.85-1.80)	0.26	1.11 (0.79-1.56)	0.55	
5-6 per week	8	7	0.86 (0.55-1.32)	0.49	0.89 (0.59-1.35)	0.59	0.81 (0.52-1.25)	0.34	
At least 1 per day	313	169	1.18 (0.89-1.56)	0.25	1.17 (0.88-1.56)	0.29	1.06 (0.80-1.42)	0.68	
Hot chocolate									
Never/less than 1 per month	311	170	ref	.	ref	.	ref	.	0.20
1-3 per month	22	20	0.92 (0.71-1.19)	0.53	0.93 (0.72-1.18)	0.53	0.86 (0.65-1.13)	0.27	
1 per week	17	10	0.79 (0.63-1.00)	0.05	0.83 (0.66-1.04)	0.10	0.79 (0.62-1.02)	0.07	
2-4 per week	15	9	0.96 (0.72-1.28)	0.78	0.97 (0.73-1.29)	0.83	0.95 (0.73-1.25)	0.73	
5-6 per week	0	0	-	.	-	.	-	.	
At least 1 per day	14	4	0.94 (0.70-1.26)	0.68	1.00 (0.73-1.35)	0.98	0.88 (0.59-1.31)	0.53	
Ovaltine / Horlicks									
Never/less than 1 per month	332	177	ref	.	ref	.	ref	.	0.20
1-3 per month	11	7	1.28 (0.87-1.88)	0.21	1.28 (0.84-1.95)	0.25	1.23 (0.82-1.86)	0.32	
1 per week	3	0	-	.	-	.	-	.	
2-4 per week	12	16	1.04 (0.75-1.45)	0.79	1.11 (0.79-1.55)	0.55	1.09 (0.78-1.53)	0.60	
5-6 per week	2	2	1.09 (0.93-1.28)	0.27	1.12 (0.95-1.32)	0.17	0.92 (0.74-1.15)	0.47	
At least 1 per day	19	11	1.17 (0.85-1.61)	0.33	1.23 (0.89-1.72)	0.21	1.23 (0.89-1.69)	0.21	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Table S8. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Soup									
Never/less than 1 per month	103	49	ref	.	ref	.	ref	.	0.28
1-3 per month	101	63	0.91 (0.77-1.06)	0.23	0.91 (0.78-1.07)	0.27	0.87 (0.74-1.02)	0.09	
1 per week	80	37	0.95 (0.79-1.13)	0.56	0.98 (0.82-1.16)	0.78	0.94 (0.79-1.13)	0.50	
2-4 per week	77	57	1.02 (0.81-1.29)	0.85	1.08 (0.86-1.35)	0.51	1.07 (0.88-1.31)	0.49	
5-6 per week	9	4	0.97 (0.72-1.31)	0.84	1.06 (0.75-1.50)	0.72	1.09 (0.76-1.58)	0.64	
At least 1 per day	9	3	1.03 (0.74-1.43)	0.87	1.18 (0.84-1.66)	0.35	1.01 (0.69-1.48)	0.96	
Fizzy pop (e.g. lemonade, cola)									
Never/less than 1 per month	251	146	ref	.	ref	.	ref	.	0.06
1-3 per month	23	11	1.16 (0.80-1.67)	0.44	1.15 (0.82-1.61)	0.42	1.09 (0.77-1.55)	0.63	
1 per week	23	13	1.04 (0.81-1.33)	0.77	1.00 (0.77-1.29)	0.99	0.99 (0.76-1.29)	0.95	
2-4 per week	38	23	0.94 (0.78-1.12)	0.47	0.88 (0.73-1.06)	0.19	0.89 (0.75-1.07)	0.23	
5-6 per week	10	3	0.99 (0.72-1.36)	0.96	0.98 (0.75-1.28)	0.89	0.98 (0.77-1.26)	0.90	
At least 1 per day	34	17	0.83 (0.69-0.99)	0.04	0.84 (0.70-1.01)	0.06	0.84 (0.70-1.01)	0.07	
Pure fruit juice (e.g. orange, apple)									
Never/less than 1 per month	144	69	ref	.	ref	.	ref	.	0.62
1-3 per month	33	34	0.97 (0.81-1.16)	0.76	0.98 (0.83-1.17)	0.86	0.99 (0.83-1.19)	0.95	
1 per week	38	25	1.20 (1.00-1.44)	0.05	1.19 (0.98-1.44)	0.08	1.17 (0.97-1.42)	0.10	
2-4 per week	55	31	0.94 (0.78-1.13)	0.50	0.95 (0.80-1.14)	0.61	1.01 (0.83-1.23)	0.92	
5-6 per week	3	1	1.52 (1.25-1.85)	0.00	1.56 (1.27-1.92)	0.00	1.59 (1.14-2.22)	0.01	
At least 1 per day	106	53	1.01 (0.84-1.22)	0.90	1.01 (0.84-1.22)	0.92	1.05 (0.86-1.27)	0.65	
Fruit squash or cordial									
Never/less than 1 per month	202	114	ref	.	ref	.	ref	.	1.00
1-3 per month	20	6	1.18 (0.79-1.75)	0.42	1.18 (0.79-1.76)	0.42	1.14 (0.79-1.64)	0.48	
1 per week	32	25	1.19 (0.95-1.49)	0.13	1.18 (0.94-1.46)	0.15	1.15 (0.93-1.43)	0.21	
2-4 per week	37	17	0.96 (0.75-1.23)	0.75	0.96 (0.74-1.24)	0.74	0.90 (0.69-1.18)	0.46	
5-6 per week	6	3	0.72 (0.57-0.91)	0.01	0.76 (0.59-0.99)	0.04	0.77 (0.62-0.95)	0.02	
At least 1 per day	82	48	1.01 (0.85-1.20)	0.90	1.02 (0.85-1.21)	0.85	1.03 (0.87-1.23)	0.72	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).

Table S8. (continued)									
			Model 1*		Model 2**		Model 3***		
	n	events	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	p trend
Milk									
Never/less than 1 per month	273	160	ref	.	ref	.	ref	.	0.35
1-3 per month	12	4	1.10 (0.79-1.53)	0.57	1.05 (0.73-1.50)	0.80	1.09 (0.85-1.41)	0.50	
1 per week	8	2	2.08 (1.39-3.12)	0.00	2.01 (1.37-2.96)	0.00	1.92 (1.39-2.65)	0.00	
2-4 per week	28	10	0.95 (0.72-1.26)	0.74	0.94 (0.72-1.24)	0.66	0.89 (0.66-1.20)	0.46	
5-6 per week	5	4	0.74 (0.60-0.92)	0.01	0.76 (0.63-0.92)	0.00	0.76 (0.57-1.02)	0.06	
At least 1 per day	53	33	1.15 (0.94-1.42)	0.18	1.16 (0.95-1.42)	0.14	1.19 (0.96-1.46)	0.11	
Water (tap, filtered, or bottled)									
Never/less than 1 per month	50	32	ref	.	ref	.	ref	.	0.57
1-3 per month	5	2	0.79 (0.64-0.98)	0.03	0.74 (0.54-1.00)	0.05	0.90 (0.68-1.19)	0.47	
1 per week	9	10	0.98 (0.71-1.36)	0.91	0.94 (0.67-1.31)	0.70	1.01 (0.69-1.47)	0.96	
2-4 per week	25	12	0.89 (0.68-1.16)	0.38	0.89 (0.68-1.17)	0.41	0.90 (0.68-1.19)	0.48	
5-6 per week	11	6	0.80 (0.60-1.08)	0.15	0.80 (0.59-1.08)	0.14	0.72 (0.51-1.02)	0.07	
At least 1 per day	279	151	0.99 (0.83-1.18)	0.87	0.97 (0.81-1.16)	0.76	1.04 (0.86-1.26)	0.66	

*Model 1 was unadjusted, **Model 2 was adjusted for age, sex, and smoking status, ***Model 3 was adjusted for age, sex, smoking status, and tumour stage, grade, size and multiplicity, and re-resection of a bladder tumour (second transurethral resection).